Genprex, Inc. (GNPX) stock
GNPXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.67−0.23 (-12.08%)
Close on Nov 17, 2026Market cap $1.37MP/E –Yield –
Genprex operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Genprex's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.56M. For fiscal 2025 it was -$15.31M. The highest annual figure on record is -$1.25M in fiscal 2016.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.31M | – |
| FY2024 | Dec 31, 2024 | -$17.92M | – |
| FY2023 | Dec 31, 2023 | -$24.74M | – |
| FY2022 | Dec 31, 2022 | -$17.62M | – |
| FY2021 | Dec 31, 2021 | -$14.28M | – |
| FY2020 | Dec 31, 2020 | -$13.94M | – |
| FY2019 | Dec 31, 2019 | -$6.92M | – |
| FY2018 | Dec 31, 2018 | -$6.85M | – |
| FY2017 | Dec 31, 2017 | -$2.17M | – |
| FY2016 | Dec 31, 2016 | -$1.25M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.10M | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.19M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.19M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.57M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.74M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$6.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.48M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$3.22M | – |
| Q3 FY2021 | Sep 30, 2021 | -$2.63M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.47M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.51M | – |
| Q1 FY2020 | Mar 31, 2020 | -$4.52M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.57M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.64M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.06M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.47M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$203.71K | – |
| Q4 FY2017 | Dec 31, 2017 | -$211.57K | – |
| Q3 FY2017 | Sep 30, 2017 | -$638.94K | – |
| Q2 FY2017 | Jun 30, 2017 | -$671.78K | – |
| Q1 FY2017 | Mar 31, 2017 | -$649.31K | – |
| Q4 FY2016 | Dec 31, 2016 | -$848.64K | – |
See a number that looks wrong?